Abstract 349P
Background
Indolent lymphomas, a heterogeneous group of non-Hodgkin lymphomas, exhibit a slow-growing nature and pose distinct clinical challenges due to their potential for relapse and transformation. While standard therapies have demonstrated efficacy in controlling disease progression, efforts to enhance treatment outcomes have led to investigations into combination regimens. Lenalidomide, an immunomodulatory agent with antiangiogenic and antitumor properties, has shown promise in various hematological malignancies. This meta-analysis aim to assess the impact of adding lenalidomide to standard therapy on overall survival (OS) and progression-free survival (PFS) in patients with indolent lymphoma.
Methods
A comprehensive search strategy was employed to identify relevant studies from electronic databases (PubMed, Embase, Web of Science) up to August 2023. Inclusion criteria encompassed randomized controlled trials (RCTs) that compared lenalidomide + standard therapy versus standard therapy alone in patients with indolent lymphoma. Pooled hazard ratios (HRs) for OS and PFS were calculated using random-effects models. Heterogeneity of the pooled analysis was measured by the chi-squared test and I2 statistic. All statistical analyses were conducted using RevMan software (version 5.4; Cochrane Collaboration, London, UK).
Results
The initial search yielded 573 articles, of which 4 randomized controlled trials (RCTs) met the eligibility criteria for inclusion in the meta-analysis. The combined data indicated that there was no statistically significant difference in OS (HR: 0.90; 95% CI: 0.59-1.38; p = 0.63; I2 = 24%) and PFS (HR: 0.76; 95% CI: 0.50-1.50; p = 0.20; I2 = 88%) between patients treated with lenalidomide + standard therapy and those receiving standard therapy alone for indolent lymphoma. Moreover, the use of lenalidomide was not significantly associated with neutropenia (OR: 2.76; 95% CI: 0.72-10.50; p = 0.14; I2 = 95%).
Conclusions
Incorporation of lenalidomide into standard therapy does not yield benefits in both OS and PFS. Due to heterogeneity in PFS and neutropenia pooled analysis, further trials are needed to confirm the results.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
551P - Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
Presenter: Andrea Knox
Session: Poster Display
Resources:
Abstract
552P - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Yasushi Goto
Session: Poster Display
Resources:
Abstract
553P - Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong
Presenter: Janet Du
Session: Poster Display
Resources:
Abstract
554P - Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study
Presenter: Kazuhito Miyazaki
Session: Poster Display
Resources:
Abstract
555P - Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong
Presenter: Jason C S Ho
Session: Poster Display
Resources:
Abstract
556P - Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
Presenter: xuezhi Hao
Session: Poster Display
Resources:
Abstract
557P - Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Presenter: Shasha Wang
Session: Poster Display
Resources:
Abstract
558P - Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK+ NSCLC in South Korea
Presenter: Jeong Eun Lee
Session: Poster Display
Resources:
Abstract
559P - Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC
Presenter: Zhaohui Arter
Session: Poster Display
Resources:
Abstract
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract